A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESOLVE-IT
  • Sponsors Genfit
  • Most Recent Events

    • 11 Apr 2018 According to a Genfit media release, the company has announced that they have reached the target recruitment for the interim cohort analysis, also recruitment has also been achieved for the exploratory arm of patients with F1 stage fibrosis.
    • 28 Mar 2018 According to a Genfit media release, data from this trial will be presented at the International Liver Congress 2018.
    • 13 Mar 2018 According to a Genfit media release, an update on the enrollment of the first group of approximately 1,000 patients from this trial will be presented the EASL Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top